Clinical trials · Providence, RI
Alzheimer’s disease clinical trials in Providence
We’re tracking 29 recruiting alzheimer’s disease studies with a site in or near Providence — including Phase 1, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies near Providence
- NCT06647498RecruitingPhase 2/Phase 3
Study of a treatment for early-onset Alzheimer's caused by a gene change
This study tests a potential disease-modifying treatment for people who have a specific gene mutation that causes early-onset Alzheimer's disease. The goal is to see if the treatment can delay or prevent symptoms.
Providence, Rhode IslandAges 18 years+ - NCT06416072Enrolling by invitation
Blood marker study for people not eligible for Alzheimer's prevention trials
This study looks at blood markers in people who were part of an early Alzheimer's prevention study but did not qualify for it because their amyloid levels were too low. It aims to understand brain changes and possibly find ways to detect Alzheimer's even earlier.
Providence, Rhode IslandAges 55–80 - NCT07177352RecruitingPhase 3
Screening for Roche Alzheimer's studies
This is a screening study to find people who might be eligible for other Alzheimer's drug studies run by the same company. It helps match you to a treatment trial if you qualify.
Providence, Rhode IslandAges 50–90 - NCT05457998Enrolling by invitation
Study of Alzheimer’s brain markers using memory testing
This trial looks for signs of Alzheimer’s disease in the brain by using memory and thinking tests, and related study procedures. It may help researchers find better ways to identify Alzheimer’s-related changes earlier.
Providence, Rhode IslandAges 50–80 - NCT05617014Enrolling by invitation
ADNI4 study for early Alzheimer’s with brain imaging tests
This study enrolls people with no memory impairment, mild memory problems, or mild Alzheimer’s dementia to test how brain scans and cognitive tests relate to Alzheimer’s disease. It may help by contributing to better early diagnosis and by letting you see whether you fit into the study’s imaging and blood-test pathway.
Providence, Rhode IslandAges 55–90 - NCT04500847RecruitingPhase 1
Testing repurposed HIV-like drugs for early Alzheimer’s symptoms
This Phase 1 study tests whether an existing type of anti-viral medicine (nucleoside reverse transcriptase inhibitors) can help people with early Alzheimer’s disease. It also focuses on safety and proper dosing while measuring brain-related changes and memory-related symptoms.
Providence, Rhode IslandAges 50–85 - NCT07169578RecruitingPhase 3
A study of trontinemab for early Alzheimer's disease
This trial tests a new drug called trontinemab for people with early Alzheimer's disease. The goal is to see if it can help slow down memory and thinking problems.
Providence, Rhode IslandAges 50–90 - NCT05980949RecruitingPhase 3
Long-term safety study of KarXT for Alzheimer's psychosis
This trial tests the long-term safety of an investigational drug called KarXT for people with psychosis caused by Alzheimer's disease. It is for those who have already completed a previous KarXT study and want to continue treatment.
Providence, Rhode IslandAges 55–90 - NCT00869817Recruiting
Study for adults at risk of inherited Alzheimer’s
This study follows people who are at risk for a specific inherited form of Alzheimer’s disease (because a parent has it). It helps researchers learn how the disease starts and changes over time, especially in people who still feel cognitively normal.
Providence, Rhode IslandAges 18 years+ - NCT05552157RecruitingPhase 2/Phase 3
Study of treatments for early onset Alzheimer's caused by genetic mutations
This trial tests potential treatments for people who are at risk for or have early onset Alzheimer's disease due to a specific genetic mutation. It aims to find treatments that could slow or prevent symptoms.
Providence, Rhode IslandAges 18 years+ - NCT05543681RecruitingPhase 2
Study drug for agitation in Alzheimer’s dementia with caregiver support
This Phase 2 trial tests a study medicine to reduce “agitation” behaviors in people with Alzheimer’s dementia. You and your caregiver would complete required assessments and may need genetic and blood testing to check how the body handles the drug.
Providence, Rhode IslandAges 60 years+ - NCT06585787RecruitingPhase 3
Testing KarXT for psychosis in Alzheimer’s disease
This study tests an investigational medication (KarXT) for treating psychosis—hallucinations or delusions—in people with Alzheimer’s disease. It aims to see if the drug can reduce these symptoms safely and effectively.
Providence, Rhode IslandAges 55–90 - NCT06584357Recruiting
Digital and blood markers linked to brain scans in older adults
This study is looking for older adults (60–90) who are either cognitively normal, have mild cognitive impairment (MCI), or have mild-to-moderate Alzheimer's dementia. It aims to see how digital tests and blood-based markers relate to brain scans (amyloid and tau PET). You will need a study partner, undergo MRI and PET scans, and give blood samples.
East Providence, Rhode IslandAges 60–90 - NCT06976216RecruitingPhase 3
Study of KarXT plus KarX-EC for Alzheimer's cognitive symptoms
This trial tests a new combination treatment (KarXT plus KarX-EC) to see if it can help with thinking and memory problems caused by Alzheimer's disease. It is for people with mild to moderate Alzheimer's who have a caregiver available.
East Providence, Rhode IslandAges 60–85 - NCT07011732RecruitingPhase 3
Testing a drug for Alzheimer's-related agitation
This study tests an experimental drug (KarXT) to see if it safely reduces agitation in people with Alzheimer's disease. It may help if you or your loved one experiences restlessness, aggression, or irritability related to Alzheimer's.
Foxborough, MassachusettsAges 55–90 - NCT06808984RecruitingPhase 2
Testing a new drug for agitation in Alzheimer's disease
This trial tests an investigational drug called BMS-986368 to see if it can safely reduce agitation in people with Alzheimer's disease. You may be able to join if you have Alzheimer's with confirmed biomarkers and experience agitation that has been going on for at least 4 weeks.
Foxborough, MassachusettsAges 55–90 - NCT05641688RecruitingPhase 3
PET brain scan study for people with terminal illness
This Phase 3 study tests an amyloid/tau PET brain imaging agent (called [18F]PI-2620). It aims to see how well the scan helps with brain pathology findings in people who are expected to have a life expectancy of 1 year or less.
Braintree, MassachusettsAges 50 years+ - NCT06821568Recruiting
Home brain stimulation for memory and walking concerns
This study tests if a gentle brain-stimulation device used at home can help older adults who have both memory worries and slower walking. A study partner will help you use the device.
Roslindale, MassachusettsAges 65–90 - NCT06937229RecruitingPhase 3
Long-term study of KarXT for agitation in Alzheimer's
This trial tests if KarXT, taken with KarX-EC, is safe and effective for long-term treatment of agitation in Alzheimer's disease. It is for people who already completed a previous KarXT study.
Worcester, MassachusettsAges 55–90 - NCT07011745RecruitingPhase 3
Study of KarXT for Alzheimer's Agitation
This study tests a new drug combination (KarXT + KarX-EC) to see if it can safely reduce agitation in people with Alzheimer's disease. It may help if you or your loved one has bothersome agitation that affects daily life.
Worcester, MassachusettsAges 55–90 - NCT07602582RecruitingPhase 3
Donanemab Extension Study for Alzheimer's Disease
This is a follow-up study for people who already completed a previous donanemab trial (AACM). Donanemab is a medication designed to slow cognitive decline in early Alzheimer's disease by targeting amyloid buildup in the brain.
Newton, MassachusettsAges 55 years+ - NCT06245031Enrolling by invitation
Long-term follow-up of sensory stimulation for Alzheimer's
This is a follow-up study for people who already completed the 12-month Hope Study (CA-0011). It tests long-term safety and effects of a gentle sensory stimulation device (light and sound) for Alzheimer's disease. You will continue using the device at home with a study partner.
Newton, MassachusettsAges 50–92 - NCT07033494RecruitingPhase 2
Study of MK-2214 for early Alzheimer's disease
This trial tests an experimental medicine called MK-2214 for people with early Alzheimer's (mild cognitive impairment or mild dementia). The goal is to see if it can slow memory and thinking problems.
Newton, MassachusettsAges 50–85 - NCT07420075Enrolling by invitation
Alzheimer's registry for people with memory problems
This registry collects information from people with mild cognitive impairment or Alzheimer's disease who are starting a new medication. It helps researchers learn more about these conditions and their treatments over time.
Waltham, MassachusettsAges 18 years+
Hear when a new Alzheimer’s disease trial opens near Providence, RI
We’ll email you when one opens near Providence, RI — at most once a week, no account needed, unsubscribe anytime.
Alzheimer’s disease trials in other cities
Where these studies are running near Providence
Institutions with a site for the recruiting alzheimer’s disease studies listed above.
- Butler Hospital · 10 studies
- Boston Center for Memory · 8 studies
- Local Institution · 3 studies
- Headlands Research Eastern MA · 2 studies
- Rhode Island Hospital · 2 studies
- Adams Clinical
- Alzheimer's Disease Center
- Boston Neuro Research Center
What taking part in a alzheimer’s disease study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Looking wider? See all recruiting alzheimer’s disease studies in Rhode Island.
Common questions
- Are there alzheimer’s disease clinical trials near Providence?
- Yes. We're currently tracking 29 recruiting alzheimer’s disease studies with a site near Providence, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a alzheimer’s disease study near Providence?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Providence to take part?
- Not necessarily. These studies have a site near Providence, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a alzheimer’s disease trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New alzheimer’s disease studies open near Providence regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.